Archives

Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has built a business model centered on personalized, subscription-based care that prioritizes convenience, accessibility and affordability. It offers recurring treatment plans for a wide range of conditions — from dermatology and mental health to sexual wellness and weight management — through its digital […]

Open Season starts Monday and feds face rising premiums and tough choices on coverage

  Interview transcript: Terry Gerton: Open Season kicks off today. People might have been a little distracted by all the other things that are happening in the federal government and with the federal workforce, but if they wake up this morning and they’re listening to us, they go, ‘Oh my goodness, it’s Open Season.’ What should […]

Questions swirl after Trump’s GLP-1 pricing deal announcement

At a White House event Thursday, President Trump announced deals with drug makers Novo Nordisk and Eli Lilly to offer their popular GLP-1 obesity and diabetes drugs at lower prices for some Americans, namely some on Medicare and Medicaid plans. But questions linger about the significance of the deal. According to the announcement, Medicare and […]

Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call

On its third-quarter conference call held on Nov. 4, Pfizer PFE shed light on the two topics for which it has been in the news lately — the drug pricing deal with the Trump administration and the battle with Novo Nordisk NVO related to the Metsera MTSR buyout. Pfizer’s Metsera Buyout in Jeopardy? Pfizer is locked […]

Weight-loss therapy goes pill-to-shot with higher efficacy, convenience

Sales of Novo Nordisk’s oral weight-loss drug Rybelsus have plateaued as Indians increasingly shift to injectable GLP-1 drugs like Eli Lilly’s Mounjaro, which has captured ₹450 crore in seven months. Injectables offer higher efficacy and convenience, though experts expect orals to rebound once higher-dose, cheaper versions launch post-2026.

Novo Nordisk shares dip after obesity drug price deal | REUTERS

Shares in Novo Nordisk fell as much as 3% after the Danish drugmaker and US rival Eli Lilly agreed with the US government to lower prices of their blockbuster GLP-1 weight-loss drugs. #News #Reuters #Newsfeed Read the story here: https://reut.rs/4nJ11dF 👉 Subscribe: http://smarturl.it/reuterssubscribe Keep up with the latest news from around the world: https://www.reuters.com/ Follow […]